$2.85
0.87% yesterday
Nasdaq, Jun 30, 10:00 pm CET
ISIN
US83558L1052
Symbol
SNOA
Sector
Industry

Sonoma Pharmaceuticals, Inc. Stock price

$2.85
-0.63 18.01% 1M
+0.10 3.45% 6M
+0.16 5.76% YTD
-1.76 38.18% 1Y
-55.56 95.13% 3Y
-139.56 98.00% 5Y
-1,279.66 99.78% 10Y
-49,137.16 99.99% 20Y
Nasdaq, Closing price Mon, Jun 30 2025
-0.03 0.87%
ISIN
US83558L1052
Symbol
SNOA
Sector
Industry

Key metrics

Basic
Market capitalization
$4.7m
Enterprise Value
$-440.0k
Net debt
positive
Cash
$5.4m
Shares outstanding
1.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.33 | 0.24
EV/Sales
negative | negative
EV/FCF
2.56
P/B
1.06
Financial Health
Equity Ratio
32.21%
Return on Equity
-78.37%
ROCE
-38.69%
ROIC
-65.65%
Debt/Equity
0.05
Financials (TTM | estimate)
Revenue
$14.3m | $19.8m
EBITDA
$-3.6m | -
EBIT
$-3.7m
Net Income
$-3.5m | $-3.0m
Free Cash Flow
$-170.0k
Growth (TTM | estimate)
Revenue
12.17% | 38.52%
EBITDA
21.19% | -
EBIT
21.11%
Net Income
28.36% | 14.16%
Free Cash Flow
92.98%
Margin (TTM | estimate)
Gross
38.25%
EBITDA
-25.00% | -
EBIT
-25.97%
Net
-24.20% | -15.01%
Free Cash Flow
-1.18%
More
EPS
$-2.14
FCF per Share
$-0.10
Short interest
1.79%
Employees
10.00
Rev per Employee
$1.43m
Show more

Is Sonoma Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,948 stocks worldwide.

Sonoma Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Sonoma Pharmaceuticals, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Sonoma Pharmaceuticals, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Sonoma Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
14 14
12% 12%
100%
- Direct Costs 8.82 8.82
14% 14%
62%
5.47 5.47
9% 9%
38%
- Selling and Administrative Expenses 7.36 7.36
3% 3%
52%
- Research and Development Expense 1.81 1.81
4% 4%
13%
-3.57 -3.57
21% 21%
-25%
- Depreciation and Amortization 0.14 0.14
22% 22%
1%
EBIT (Operating Income) EBIT -3.71 -3.71
21% 21%
-26%
Net Profit -3.46 -3.46
28% 28%
-24%

In millions USD.

Don't miss a Thing! We will send you all news about Sonoma Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sonoma Pharmaceuticals, Inc. Stock News

Neutral
Accesswire
13 days ago
Revenues increased 9% in Q4 2025 compared to Q4 2024, and 12% in FY 2025 compared to FY 2024 Net loss improved 27% in Q4 2025 compared to Q4 2024, and 29% in FY 2025 compared to FY 2024 EBITDA loss improved 59% in Q4 2025 compared to Q4 2024, and 17% in FY 2025 compared to FY 2024 BOULDER, CO / ACCESS Newswire / June 17, 2025 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA),a global healthcare lead...
Neutral
Accesswire
2 months ago
BOULDER, CO / ACCESS Newswire / April 22, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced the registra...
Neutral
Accesswire
4 months ago
BOULDER, CO / ACCESS Newswire / March 10, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced the registra...
More Sonoma Pharmaceuticals, Inc. News

Company Profile

Sonoma Pharmaceuticals, Inc. engages in identifying, developing, and commercializing therapies for chronic skin conditions. The company offers solutions in dermatology, animal healthcare, and advanced tissue care product areas. Its products target skin diseases including acne, atopic dermatitis, scarring, infections, itch, pain, and harmful inflammatory responses. The company was founded by Hojabr Alimi and Linda Alimi in April 1999 and is headquartered in Petaluma, CA.

Head office United States
CEO Amy Trombly
Employees 10
Founded 1999
Website sonomapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today